Cargando…

Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial

BACKGROUND: Active surveillance has been proposed for patients with oesophageal cancer in whom there is a complete clinical response after neoadjuvant chemoradiotherapy (nCRT). However, endoscopic biopsies have limited negative predictive value in detecting residual disease. This study determined th...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Wilk, B. J., Eyck, B. M., Doukas, M., Spaander, M. C. W., Schoon, E. J., Krishnadath, K. K., Oostenbrug, L. E., Lagarde, S. M., Wijnhoven, B. P. L., Looijenga, L. H. J., Biermann, K., van Lanschot, J. J. B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689829/ https://www.ncbi.nlm.nih.gov/pubmed/32757307 http://dx.doi.org/10.1002/bjs.11760

Ejemplares similares

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol
por: Noordman, Bo Jan, et al.
Publicado: (2015)

Active surveillance of oesophageal cancer after response to neoadjuvant chemoradiotherapy: dysphagia is uncommon
por: Valkema, Maria J, et al.
Publicado: (2023)

Loss of SRY‐box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma
por: ten Kate, F. J. C., et al.
Publicado: (2017)

Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer
por: Eyck, Ben M., et al.
Publicado: (2021)

Pattern of recurrence in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer
por: de Jongh, M, et al.
Publicado: (2021)

The effectiveness of neoadjuvant chemoradiotherapy in oesophageal adenocarcinoma with presence of extracellular mucin, signet‐ring cells, and/or poorly cohesive cells
por: Valkema, Maria J, et al.
Publicado: (2023)

Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer
por: Eyck, Ben M, et al.
Publicado: (2022)

Do pathologists agree with each other on the histological assessment of pT1b oesophageal adenocarcinoma?
por: Gotink, Annieke W, et al.
Publicado: (2018)

Fixed Size of Enlarged Calcified Lymph Nodes in Esophageal Adenocarcinoma despite Complete Remission
por: Grotenhuis, B.A., et al.
Publicado: (2009)

Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: multicentre East Asian and Dutch database comparison
por: Eyck, Ben M, et al.
Publicado: (2022)

Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma
por: Tuynman, J B, et al.
Publicado: (2008)

Olfactomedin 4 (OLFM4) expression is associated with nodal metastases in esophageal adenocarcinoma
por: Suzuki, Lucia, et al.
Publicado: (2019)

A prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of Surgery As Needed for Oesophageal cancer-2
por: van der Zijden, Charlène J., et al.
Publicado: (2023)

The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction
por: Valkema, M. J., et al.
Publicado: (2022)

Early onset esophageal adenocarcinoma: a distinct molecular entity?
por: van Nistelrooij, Anna M.J., et al.
Publicado: (2016)

External validation of (18)F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy
por: Valkema, Maria J., et al.
Publicado: (2023)

Germline variant in MSX1 identified in a Dutch family with clustering of Barrett’s esophagus and esophageal adenocarcinoma
por: van Nistelrooij, A. M. J., et al.
Publicado: (2017)

Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma
por: Ten Kate, Fiebo J.C., et al.
Publicado: (2017)

Molecular clonality analysis of esophageal adenocarcinoma by multiregion sequencing of tumor samples
por: van Nistelrooij, Anna M. J., et al.
Publicado: (2017)

Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial
por: Noordman, Bo Jan, et al.
Publicado: (2018)

Characteristics Predicting Short-Term and Long-Term Health-Related Quality of Life in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy and Esophagectomy
por: van der Wilk, Berend J., et al.
Publicado: (2023)

Chemotherapy aNd chemoradiotherapy for adenocarcinoma of the OESophagus and esophagogastric junction with oligometastases: Protocol of the TNT-OES-1 trial
por: van der Zijden, Charlène J., et al.
Publicado: (2022)

International benchmarking in oesophageal and gastric cancer surgery
por: Busweiler, L. A. D., et al.
Publicado: (2018)

Delay in Diagnostic Workup and Treatment of Esophageal Cancer
por: Grotenhuis, Brechtje A., et al.
Publicado: (2009)

Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: The NOSANO‐study
por: Hermus, Merel, et al.
Publicado: (2022)

Transhiatal vs extended transthoracic resection in oesophageal carcinoma: patients' utilities and treatment preferences
por: de Boer, A G E M, et al.
Publicado: (2002)

ICG‐fluorescence angiography assessment of colon interposition for oesophageal cancer – A Video Vignette
por: Galema, Hidde A., et al.
Publicado: (2022)

Use of immunohistochemical biomarkers as independent predictor of neoplastic progression in Barrett's oesophagus surveillance: A systematic review and meta-analysis
por: Janmaat, Vincent T., et al.
Publicado: (2017)

Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer
por: Noordman, B. J., et al.
Publicado: (2019)

Value of cyclin A immunohistochemistry for cancer risk stratification in Barrett esophagus surveillance: A multicenter case–control study
por: van Olphen, Sophie H., et al.
Publicado: (2016)

Single nucleotide polymorphisms in CRTC1 and BARX1 are associated with esophageal adenocarcinoma
por: van Nistelrooij, Anna M. J., et al.
Publicado: (2015)

Staged left ventricular recruitment facilitated by Sano conduit upsizing
por: Prabhu, Neel K., et al.
Publicado: (2022)

Supervised exercise after oesophageal cancer surgery: the PERFECT multicentre randomized clinical trial
por: van Vulpen, J K, et al.
Publicado: (2021)

Interventions that Facilitate Shared Decision-Making in Cancers with Active Surveillance as Treatment Option: a Systematic Review of Literature
por: Collée, G. E., et al.
Publicado: (2020)

Prognostic Value of Body Mass Index on Short-Term and Long-Term Outcome after Resection of Esophageal Cancer
por: Grotenhuis, B. A., et al.
Publicado: (2010)

Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study
por: Zhang, Xiaobin, et al.
Publicado: (2020)

Systematic review of the introduction and evaluation of magnetic augmentation of the lower oesophageal sphincter for gastro‐oesophageal reflux disease
por: Kirkham, E. N., et al.
Publicado: (2019)

The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma
por: van Hootegem, Sander J. M., et al.
Publicado: (2019)

Human oesophageal adenocarcinoma cell lines JROECL 47 and JROECL 50 are admixtures of the human colon carcinoma cell line HCT 116
por: Wijnhoven, B P L, et al.
Publicado: (2000)

El niño Sano
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_d6coknrf6varku87jkscl5on73